Richard J. Jones

24.4k total citations · 3 hit papers
333 papers, 14.4k citations indexed

About

Richard J. Jones is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Richard J. Jones has authored 333 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 243 papers in Hematology, 98 papers in Oncology and 84 papers in Immunology. Recurrent topics in Richard J. Jones's work include Hematopoietic Stem Cell Transplantation (166 papers), Acute Myeloid Leukemia Research (84 papers) and Acute Lymphoblastic Leukemia research (48 papers). Richard J. Jones is often cited by papers focused on Hematopoietic Stem Cell Transplantation (166 papers), Acute Myeloid Leukemia Research (84 papers) and Acute Lymphoblastic Leukemia research (48 papers). Richard J. Jones collaborates with scholars based in United States, Canada and Italy. Richard J. Jones's co-authors include Robert A. Brodsky, Ephraim J. Fuchs, William Matsui, Leo Luznik, Carol Ann Huff, Ashkan Emadi, James Barber, Richard F. Ambinder, Javier Bolaños‐Meade and Carole B. Miller and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Richard J. Jones

321 papers receiving 14.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclophosphamide and cancer: golden anniversary

2009 731 citations Ashkan Emadi, Richard J. Jones et al. Nature Reviews Clinical Oncology profile →
Characterization of clonogenic multiple myeloma cells

2003 600 citations William Matsui, Carol Ann Huff et al. Blood profile →
Decreased Erythropoietin Response in Patients with the Anemia of Cancer

1990 507 citations Carole B. Miller, Richard J. Jones et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard J. Jones United States	66	7.8k	4.3k	3.8k	3.3k	2.4k	333	14.4k
Giuseppe Leone Italy	63	6.6k 0.9×	2.6k 0.6×	2.6k 0.7×	4.4k 1.3×	3.8k 1.6×	604	16.2k
Börje S. Andersson United States	60	9.6k 1.2×	3.7k 0.9×	3.1k 0.8×	2.1k 0.6×	2.3k 1.0×	326	13.4k
Edo Vellenga Netherlands	72	8.7k 1.1×	5.3k 1.2×	3.4k 0.9×	7.6k 2.3×	2.7k 1.2×	487	18.7k
Sergio Amadori Italy	58	9.9k 1.3×	3.4k 0.8×	1.8k 0.5×	4.1k 1.2×	3.7k 1.6×	363	15.5k
Magnus Björkholm Sweden	66	5.6k 0.7×	4.0k 0.9×	2.5k 0.6×	5.0k 1.5×	4.7k 2.0×	488	16.3k
Carlos E. Bueso‐Ramos United States	59	6.0k 0.8×	3.0k 0.7×	2.3k 0.6×	5.8k 1.7×	4.3k 1.8×	386	14.7k
Daniel J. DeAngelo United States	60	9.0k 1.2×	4.3k 1.0×	1.9k 0.5×	6.2k 1.8×	3.9k 1.7×	444	16.3k
Roy Fleischmann United States	69	8.1k 1.0×	2.8k 0.7×	6.4k 1.7×	1.6k 0.5×	3.9k 1.7×	347	22.9k
Alan F. List United States	68	15.4k 2.0×	4.2k 1.0×	2.9k 0.8×	8.3k 2.5×	6.5k 2.8×	621	21.9k
Wendy Stock United States	54	6.1k 0.8×	3.6k 0.8×	1.3k 0.4×	3.5k 1.1×	2.3k 1.0×	463	12.1k

Countries citing papers authored by Richard J. Jones

Since Specialization

Citations

This map shows the geographic impact of Richard J. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard J. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard J. Jones more than expected).

Fields of papers citing papers by Richard J. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard J. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard J. Jones. The network helps show where Richard J. Jones may publish in the future.

Co-authorship network of co-authors of Richard J. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Richard J. Jones. A scholar is included among the top collaborators of Richard J. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard J. Jones. Richard J. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zahurak, Marianna, et al.. (2024). Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy. 30(6). 588–596. 1 indexed citations

DeZern, Amy E., Marianna Zahurak, Heather J. Symons, et al.. (2023). Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 141(25). 3031–3038. 18 indexed citations

Ghiaur, Gabriel, et al.. (2023). Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4. Cancer. 129(11). 1744–1751. 6 indexed citations

Karantanos, Theodoros, Patric Teodorescu, Brandy Perkins, et al.. (2022). The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Science Advances. 8(7). eabl8952–eabl8952. 10 indexed citations

Ambinder, Alexander J., Tania Jain, Hua‐Ling Tsai, et al.. (2022). HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Advances. 6(14). 4335–4346. 15 indexed citations

DeZern, Amy E., Hua‐Ling Tsai, Philip Imus, et al.. (2021). Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Advances. 5(5). 1360–1368. 53 indexed citations

Webster, Jonathan, Tara M. Robinson, Amanda L. Blackford, et al.. (2021). A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research. 111. 106737–106737. 4 indexed citations

Fuchs, Ephraim J., Paul V. O’Donnell, Mary Eapen, et al.. (2020). Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 137(3). 420–428. 106 indexed citations

Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2020). Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). Blood. 136(Supplement 1). 40–40. 1 indexed citations

10.

Imus, Philip, Amanda L. Blackford, Maria Bettinotti, et al.. (2019). Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(12). 2431–2437. 56 indexed citations

11.

Hayley, S., Li Li, Alice Can Ran Qin, et al.. (2017). Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies. Cancer Research. 77(20). 5554–5563. 32 indexed citations

12.

Bolaños‐Meade, Javier, Ephraim J. Fuchs, Leo Luznik, et al.. (2012). HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 120(22). 4285–4291. 306 indexed citations

13.

Smith, B. Douglas, Yvette L. Kasamon, Jeanne Kowalski, et al.. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clinical Cancer Research. 16(1). 338–347. 77 indexed citations

14.

Peltonen, Karita, Laureen Colis, Hester Liu, et al.. (2010). Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents. PLoS ONE. 5(9). e12996–e12996. 79 indexed citations

15.

Huang, Yi, Tracy Murray Stewart, Yu Wu, et al.. (2009). Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes. Clinical Cancer Research. 15(23). 7217–7228. 158 indexed citations

16.

Emadi, Ashkan, Richard J. Jones, & Robert A. Brodsky. (2009). Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology. 6(11). 638–647. 731 indexed citations breakdown →

17.

Huff, Carol Ann, Qiuju Wang, Javier Bolaños‐Meade, et al.. (2008). Correlation of clonogenic cancer stem cell (CSC) growth with clinical outcomes in multiple myeloma (MM) patients undergoing treatment with high dose cyclophosphamide (Cy) and rituximab. Cancer Research. 68. 5 indexed citations

18.

Bolaños‐Meade, Javier, Leo Luznik, William Matsui, et al.. (2008). Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplantation. 43(6). 477–480. 10 indexed citations

19.

Jones, Richard J.. (1992). Purging With 4-Hydroperoxycyclophosphamide. Journal of Hematotherapy. 1(4). 343–348. 13 indexed citations

20.

Jones, Richard J.. (1970). Atherosclerosis : proceedings of the Second International Symposium. Springer eBooks. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact